2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. Folate Receptor (FR)
  5. Folate Receptor (FR) Inhibitor

Folate Receptor (FR) Inhibitor

Folate Receptor (FR) Isoform Comparison

Folate Receptor (FR) Inhibitors (6):

Cat. No. Product Name Effect Purity
  • HY-P992112
    Eliroptamig
    		Inhibitor
    Eliroptamig is a multispecific antibody targeting albumin, folate receptor α (FOLR1) and cluster of differentiation 3 (CD3). Eliroptamig extends its half-life by binding to albumin, while targeting FOLR1 on tumor cells and activating T cells to achieve precise tumor killing.
  • HY-P992510
    Sofetabart
    		Inhibitor
    Sofetabart (LY-4170156 Antibody) is an Fc-silenced, humanized IgG1 antibody targeting FRα, a composition of antibody drug conjugate (ADC) LY-4170156. Sofetabart can be used for the research of Platinum-resistant ovarian cancer and platinum-sensitive ovarian cancer.
  • HY-P991695
    Lazatatug
    		Inhibitor
    Lazatatug is an anti-FOLR1 IgEκ type humanized antibody with antineoplastic activity.
  • HY-16181
    EC-0225
    		Inhibitor
    EC-0225, a folate conjugate of two agents- one a potent microtubule inhibiting agent, and the second a DNA alkylating agent. EC-0225 inhibits the growth of folate receptor (FR)-positive KB cells with an IC50 of ~1 nM. EC-0225 can be selectively delivered to advanced FR-positive tumors without causing overt toxicity, such as lung carcinoma.
  • HY-P992124
    Onvontatug
    		Inhibitor
    Onvontatug (BAT8006 Antibody) is a humanized monoclonal antibody targeting folate receptor α (FRα). Onvontatug can be used to construct antibody-drug conjugates (ADCs), such as BAT8006. It is applicable to research related to platinum-resistant ovarian cancer.
  • HY-P992004
    KHK2805
    		Inhibitor
    KHK2805 (RA15-7) is a humanized antibody against folate receptor α (FOLR1), with a Kd of 0.647 nM for human FOLR1. KHK2805 binds to a unique epitope of FOLR1 and mediates antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against FOLR1-expressing cells. KHK2805 exhibits cytotoxicity against both ovarian cancer cells and Platinum (HY-W096169D)-resistant ovarian cancer cells. KHK2805 can be used for the research of tumors such as ovarian cancer.